instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the dosage of drug 'MOXETUMOMAB PASUDOTOX'? | Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox.
The purine nucleoside analogues cladribine and pentostatin are highly-active first-line therapeutic treatments for hairy cell leukemia (HCL), resulting in complete response rates of 80% to 90%. However, HCL pat... | 40 UG/KG IV 3 EVERY 28 D FOR 6 | DrugDosageText | CC BY | 34202156 | 19,520,116 | 2021-06-25 |
What was the dosage of drug 'PREDNISONE'? | Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox.
The purine nucleoside analogues cladribine and pentostatin are highly-active first-line therapeutic treatments for hairy cell leukemia (HCL), resulting in complete response rates of 80% to 90%. However, HCL pat... | 10 MG | DrugDosageText | CC BY | 34202156 | 19,788,684 | 2021-06-25 |
What was the outcome of reaction 'Multiple organ dysfunction syndrome'? | Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox.
The purine nucleoside analogues cladribine and pentostatin are highly-active first-line therapeutic treatments for hairy cell leukemia (HCL), resulting in complete response rates of 80% to 90%. However, HCL pat... | Fatal | ReactionOutcome | CC BY | 34202156 | 19,520,116 | 2021-06-25 |
What was the outcome of reaction 'Neutrophil count decreased'? | Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox.
The purine nucleoside analogues cladribine and pentostatin are highly-active first-line therapeutic treatments for hairy cell leukemia (HCL), resulting in complete response rates of 80% to 90%. However, HCL pat... | Fatal | ReactionOutcome | CC BY | 34202156 | 19,520,116 | 2021-06-25 |
What was the outcome of reaction 'Pneumonia'? | Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox.
The purine nucleoside analogues cladribine and pentostatin are highly-active first-line therapeutic treatments for hairy cell leukemia (HCL), resulting in complete response rates of 80% to 90%. However, HCL pat... | Fatal | ReactionOutcome | CC BY | 34202156 | 19,520,116 | 2021-06-25 |
What was the outcome of reaction 'Pseudomonas infection'? | Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox.
The purine nucleoside analogues cladribine and pentostatin are highly-active first-line therapeutic treatments for hairy cell leukemia (HCL), resulting in complete response rates of 80% to 90%. However, HCL pat... | Fatal | ReactionOutcome | CC BY | 34202156 | 19,520,116 | 2021-06-25 |
What was the outcome of reaction 'Septic shock'? | Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox.
The purine nucleoside analogues cladribine and pentostatin are highly-active first-line therapeutic treatments for hairy cell leukemia (HCL), resulting in complete response rates of 80% to 90%. However, HCL pat... | Fatal | ReactionOutcome | CC BY | 34202156 | 19,520,116 | 2021-06-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anal haemorrhage'. | Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma.
(1) Background: We investigated survival outcomes following first-line chemotherapy before and after approval of bevacizumab (Bev) for ovarian cancer in Japan to evaluate the efficacy of Bev for advanced... | BEVACIZUMAB | DrugsGivenReaction | CC BY | 34202220 | 19,512,257 | 2021-06-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Epistaxis'. | Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma.
(1) Background: We investigated survival outcomes following first-line chemotherapy before and after approval of bevacizumab (Bev) for ovarian cancer in Japan to evaluate the efficacy of Bev for advanced... | BEVACIZUMAB | DrugsGivenReaction | CC BY | 34202220 | 19,512,257 | 2021-06-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertension'. | Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma.
(1) Background: We investigated survival outcomes following first-line chemotherapy before and after approval of bevacizumab (Bev) for ovarian cancer in Japan to evaluate the efficacy of Bev for advanced... | BEVACIZUMAB | DrugsGivenReaction | CC BY | 34202220 | 19,512,257 | 2021-06-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Large intestinal obstruction'. | Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma.
(1) Background: We investigated survival outcomes following first-line chemotherapy before and after approval of bevacizumab (Bev) for ovarian cancer in Japan to evaluate the efficacy of Bev for advanced... | BEVACIZUMAB | DrugsGivenReaction | CC BY | 34202220 | 19,512,257 | 2021-06-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Proteinuria'. | Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma.
(1) Background: We investigated survival outcomes following first-line chemotherapy before and after approval of bevacizumab (Bev) for ovarian cancer in Japan to evaluate the efficacy of Bev for advanced... | BEVACIZUMAB | DrugsGivenReaction | CC BY | 34202220 | 19,512,257 | 2021-06-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC).
In current clinical guidelines, such as those provided by the National Comprehensive Cancer Network (NCCN), evidence for treatment is based on a small clinical trial that included patients with HLRCC. They ... | BEVACIZUMAB, ERLOTINIB HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34202275 | 19,967,048 | 2021-06-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neoplasm progression'. | Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC).
In current clinical guidelines, such as those provided by the National Comprehensive Cancer Network (NCCN), evidence for treatment is based on a small clinical trial that included patients with HLRCC. They ... | BEVACIZUMAB, ERLOTINIB | DrugsGivenReaction | CC BY | 34202275 | 19,925,065 | 2021-06-25 |
What was the administration route of drug 'ERLOTINIB'? | Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC).
In current clinical guidelines, such as those provided by the National Comprehensive Cancer Network (NCCN), evidence for treatment is based on a small clinical trial that included patients with HLRCC. They ... | Oral | DrugAdministrationRoute | CC BY | 34202275 | 20,103,718 | 2021-06-25 |
What was the dosage of drug 'ERLOTINIB HYDROCHLORIDE'? | Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC).
In current clinical guidelines, such as those provided by the National Comprehensive Cancer Network (NCCN), evidence for treatment is based on a small clinical trial that included patients with HLRCC. They ... | 150 MILLIGRAM, QD | DrugDosageText | CC BY | 34202275 | 19,967,048 | 2021-06-25 |
What was the outcome of reaction 'Neoplasm progression'? | Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC).
In current clinical guidelines, such as those provided by the National Comprehensive Cancer Network (NCCN), evidence for treatment is based on a small clinical trial that included patients with HLRCC. They ... | Recovering | ReactionOutcome | CC BY | 34202275 | 19,925,065 | 2021-06-25 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Castleman^s disease'. | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | ACITRETIN, ADALIMUMAB, APREMILAST, CYCLOSPORINE, GUSELKUMAB, IXEKIZUMAB, METHOTREXATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | ACITRETIN, ADALIMUMAB, APREMILAST, CYCLOSPORINE, GUSELKUMAB, IXEKIZUMAB, METHOTREXATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Erythrodermic psoriasis'. | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | ACITRETIN, ADALIMUMAB, APREMILAST, CYCLOSPORINE, GUSELKUMAB, IXEKIZUMAB, METHOTREXATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mantle cell lymphoma'. | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | ACITRETIN, ADALIMUMAB, APREMILAST, CYCLOSPORINE, GUSELKUMAB, IXEKIZUMAB, METHOTREXATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | ACITRETIN, ADALIMUMAB, CYCLOSPORINE, GUSELKUMAB, IXEKIZUMAB, METHOTREXATE, PREDNISOLONE, RITUXIMAB | DrugsGivenReaction | CC BY | 34202434 | 19,817,798 | 2021-06-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product effect incomplete'. | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | ACITRETIN, ADALIMUMAB, APREMILAST, CYCLOSPORINE, GUSELKUMAB, IXEKIZUMAB, METHOTREXATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
What was the administration route of drug 'RITUXIMAB'? | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34202434 | 19,817,798 | 2021-06-24 |
What was the dosage of drug 'ACITRETIN'? | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | UNK (UNKNOWN DOSE AND FREQUENCY) | DrugDosageText | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
What was the dosage of drug 'ADALIMUMAB'? | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | UNK (UNKNOWN DOSE AND FREQUENCY) | DrugDosageText | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
What was the dosage of drug 'APREMILAST'? | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | UNK (UNKNOWN DOSE AND FREQUENCY) | DrugDosageText | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
What was the dosage of drug 'CYCLOSPORINE'? | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | UNK (UNKNOWN DOSE AND FREQUENCY) | DrugDosageText | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
What was the dosage of drug 'GUSELKUMAB'? | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | UNK (UNKNOWN DOSE AND FREQUENCY) | DrugDosageText | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
What was the dosage of drug 'IXEKIZUMAB'? | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | UNK (UNKNOWN DOSE AND FREQUENCY) | DrugDosageText | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
What was the dosage of drug 'METHOTREXATE'? | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | UNK (UNKNOWN DOSE AND FREQUENCY) | DrugDosageText | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
What was the dosage of drug 'PREDNISOLONE'? | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | UNK (UNKNOWN DOSE AND FREQUENCY) | DrugDosageText | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
What was the dosage of drug 'RITUXIMAB'? | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | 375 MG/M2 EVERY 2 WEEKS, FOUR DOSES | DrugDosageText | CC BY | 34202434 | 19,817,798 | 2021-06-24 |
What was the outcome of reaction 'Castleman^s disease'? | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | Recovering | ReactionOutcome | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
What was the outcome of reaction 'Erythrodermic psoriasis'? | HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis.
A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and syste... | Recovering | ReactionOutcome | CC BY | 34202434 | 19,996,159 | 2021-06-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML), presenting as immune reconstitution inflammatory syndrome (IRIS), is a known complication of antiretroviral therapy (ART) in peop... | BICTEGRAVIR, EMTRICITABINE, METHYLPREDNISOLONE, PREDNISONE, TENOFOVIR ALAFENAMIDE | DrugsGivenReaction | CC BY | 34203265 | 20,846,910 | 2021-06-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Epstein-Barr virus infection'. | Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML), presenting as immune reconstitution inflammatory syndrome (IRIS), is a known complication of antiretroviral therapy (ART) in peop... | BICTEGRAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE, METHYLPREDNISOLONE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34203265 | 20,941,825 | 2021-06-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Paradoxical drug reaction'. | Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML), presenting as immune reconstitution inflammatory syndrome (IRIS), is a known complication of antiretroviral therapy (ART) in peop... | BICTEGRAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE, METHYLPREDNISOLONE, PREDNISONE | DrugsGivenReaction | CC BY | 34203265 | 20,877,138 | 2021-06-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rebound effect'. | Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML), presenting as immune reconstitution inflammatory syndrome (IRIS), is a known complication of antiretroviral therapy (ART) in peop... | BICTEGRAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE, METHYLPREDNISOLONE, PREDNISONE | DrugsGivenReaction | CC BY | 34203265 | 20,877,138 | 2021-06-28 |
What was the administration route of drug 'METHYLPREDNISOLONE'? | Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML), presenting as immune reconstitution inflammatory syndrome (IRIS), is a known complication of antiretroviral therapy (ART) in peop... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34203265 | 20,877,138 | 2021-06-28 |
What was the administration route of drug 'PREDNISOLONE'? | Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML), presenting as immune reconstitution inflammatory syndrome (IRIS), is a known complication of antiretroviral therapy (ART) in peop... | Oral | DrugAdministrationRoute | CC BY | 34203265 | 20,941,825 | 2021-06-28 |
What was the administration route of drug 'PREDNISONE'? | Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML), presenting as immune reconstitution inflammatory syndrome (IRIS), is a known complication of antiretroviral therapy (ART) in peop... | Oral | DrugAdministrationRoute | CC BY | 34203265 | 20,877,138 | 2021-06-28 |
What was the dosage of drug 'BICTEGRAVIR SODIUM\EMTRICITABINE\TENOFOVIR ALAFENAMIDE FUMARATE'? | Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML), presenting as immune reconstitution inflammatory syndrome (IRIS), is a known complication of antiretroviral therapy (ART) in peop... | 50 MG/EMTRICITABINE 200 MG/TENOFOVIR ALAFENAMIDE 25 MG | DrugDosageText | CC BY | 34203265 | 19,907,867 | 2021-06-28 |
What was the dosage of drug 'BICTEGRAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE'? | Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML), presenting as immune reconstitution inflammatory syndrome (IRIS), is a known complication of antiretroviral therapy (ART) in peop... | 50/200/25 MILLIGRAM | DrugDosageText | CC BY | 34203265 | 20,941,825 | 2021-06-28 |
What was the outcome of reaction 'Epstein-Barr virus infection'? | Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML), presenting as immune reconstitution inflammatory syndrome (IRIS), is a known complication of antiretroviral therapy (ART) in peop... | Recovered | ReactionOutcome | CC BY | 34203265 | 20,941,825 | 2021-06-28 |
What was the outcome of reaction 'Immune reconstitution inflammatory syndrome'? | Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML), presenting as immune reconstitution inflammatory syndrome (IRIS), is a known complication of antiretroviral therapy (ART) in peop... | Recovering | ReactionOutcome | CC BY | 34203265 | 19,907,867 | 2021-06-28 |
What was the outcome of reaction 'Paradoxical drug reaction'? | Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML), presenting as immune reconstitution inflammatory syndrome (IRIS), is a known complication of antiretroviral therapy (ART) in peop... | Recovering | ReactionOutcome | CC BY | 34203265 | 20,877,138 | 2021-06-28 |
What was the outcome of reaction 'Progressive multifocal leukoencephalopathy'? | Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML), presenting as immune reconstitution inflammatory syndrome (IRIS), is a known complication of antiretroviral therapy (ART) in peop... | Recovering | ReactionOutcome | CC BY | 34203265 | 19,907,867 | 2021-06-28 |
What was the outcome of reaction 'Rebound effect'? | Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy.
Progressive multifocal leukoencephalopathy (PML), presenting as immune reconstitution inflammatory syndrome (IRIS), is a known complication of antiretroviral therapy (ART) in peop... | Recovering | ReactionOutcome | CC BY | 34203265 | 20,877,138 | 2021-06-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood creatinine increased'. | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
OBJECTIVE
We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based ... | CYCLOPHOSPHAMIDE, FILGRASTIM, RITUXIMAB | DrugsGivenReaction | CC BY | 34204102 | 19,452,886 | 2021-06-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
OBJECTIVE
We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based ... | CYCLOPHOSPHAMIDE, FILGRASTIM, RITUXIMAB | DrugsGivenReaction | CC BY | 34204102 | 19,452,886 | 2021-06-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Febrile neutropenia'. | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
OBJECTIVE
We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based ... | CYCLOPHOSPHAMIDE, FILGRASTIM, RITUXIMAB | DrugsGivenReaction | CC BY | 34204102 | 19,452,886 | 2021-06-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Leukopenia'. | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
OBJECTIVE
We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based ... | CYCLOPHOSPHAMIDE, FILGRASTIM, RITUXIMAB | DrugsGivenReaction | CC BY | 34204102 | 19,452,886 | 2021-06-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
OBJECTIVE
We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based ... | CYCLOPHOSPHAMIDE, FILGRASTIM, RITUXIMAB | DrugsGivenReaction | CC BY | 34204102 | 19,452,886 | 2021-06-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenia'. | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
OBJECTIVE
We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based ... | CYCLOPHOSPHAMIDE, FILGRASTIM, RITUXIMAB | DrugsGivenReaction | CC BY | 34204102 | 19,452,886 | 2021-06-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
OBJECTIVE
We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based ... | CYCLOPHOSPHAMIDE, FILGRASTIM, RITUXIMAB | DrugsGivenReaction | CC BY | 34204102 | 19,452,886 | 2021-06-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vomiting'. | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
OBJECTIVE
We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based ... | CYCLOPHOSPHAMIDE, FILGRASTIM, RITUXIMAB | DrugsGivenReaction | CC BY | 34204102 | 19,452,886 | 2021-06-06 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
OBJECTIVE
We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based ... | 2.5 GRAM PER SQUARE METRE | DrugDosageText | CC BY | 34204102 | 19,452,886 | 2021-06-06 |
What was the dosage of drug 'FILGRASTIM'? | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
OBJECTIVE
We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based ... | 10 MICROGRAM/KILOGRAM, QD | DrugDosageText | CC BY | 34204102 | 19,452,886 | 2021-06-06 |
What was the dosage of drug 'RITUXIMAB'? | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
OBJECTIVE
We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based ... | 375 MILLIGRAM/SQ. METER, QWK (FOR 4 CONSECUTIVE WEEKS) | DrugDosageText | CC BY | 34204102 | 19,452,886 | 2021-06-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug interaction'. | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | ESCITALOPRAM OXALATE, LISINOPRIL, METOPROLOL, QUETIAPINE | DrugsGivenReaction | CC BY | 34204223 | 19,796,160 | 2021-06-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gait disturbance'. | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | ESCITALOPRAM OXALATE, LISINOPRIL, METOPROLOL, QUETIAPINE FUMARATE | DrugsGivenReaction | CC BY | 34204223 | 19,824,593 | 2021-06-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sleep disorder'. | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | ESCITALOPRAM OXALATE, LISINOPRIL, METOPROLOL, QUETIAPINE FUMARATE | DrugsGivenReaction | CC BY | 34204223 | 19,824,593 | 2021-06-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tachycardia'. | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | ESCITALOPRAM OXALATE, LISINOPRIL, METOPROLOL, QUETIAPINE FUMARATE | DrugsGivenReaction | CC BY | 34204223 | 19,824,593 | 2021-06-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thinking abnormal'. | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | ESCITALOPRAM OXALATE, LISINOPRIL, METOPROLOL, QUETIAPINE FUMARATE | DrugsGivenReaction | CC BY | 34204223 | 19,824,593 | 2021-06-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tremor'. | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | QUETIAPINE FUMARATE | DrugsGivenReaction | CC BY | 34204223 | 19,824,592 | 2021-06-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vertigo'. | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | ESCITALOPRAM OXALATE, LISINOPRIL, METOPROLOL, QUETIAPINE FUMARATE | DrugsGivenReaction | CC BY | 34204223 | 19,824,593 | 2021-06-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vomiting'. | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | ESCITALOPRAM OXALATE, LISINOPRIL, METOPROLOL, QUETIAPINE FUMARATE | DrugsGivenReaction | CC BY | 34204223 | 19,824,593 | 2021-06-17 |
What was the dosage of drug 'AGOMELATINE'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | 50 mg (milligrams). | DrugDosage | CC BY | 34204223 | 19,844,530 | 2021-06-17 |
What was the dosage of drug 'AZILSARTAN KAMEDOXOMIL'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | 40 mg (milligrams). | DrugDosage | CC BY | 34204223 | 19,844,530 | 2021-06-17 |
What was the dosage of drug 'CHLORTHALIDONE'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | 12.5 mg (milligrams). | DrugDosage | CC BY | 34204223 | 19,844,530 | 2021-06-17 |
What was the dosage of drug 'EPLERENONE'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | 25 mg (milligrams). | DrugDosage | CC BY | 34204223 | 19,844,530 | 2021-06-17 |
What was the dosage of drug 'METOPROLOL TARTRATE'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | 25 mg (milligrams). | DrugDosage | CC BY | 34204223 | 19,886,795 | 2021-06-17 |
What was the dosage of drug 'RIVAROXABAN'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | 20 mg (milligrams). | DrugDosage | CC BY | 34204223 | 19,844,530 | 2021-06-17 |
What was the dosage of drug 'TRAZODONE HYDROCHLORIDE'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | 150 mg (milligrams). | DrugDosage | CC BY | 34204223 | 19,844,530 | 2021-06-17 |
What was the outcome of reaction 'Constipation'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | Recovered | ReactionOutcome | CC BY | 34204223 | 19,844,530 | 2021-06-17 |
What was the outcome of reaction 'Drug interaction'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | Recovered | ReactionOutcome | CC BY | 34204223 | 19,844,580 | 2021-06-17 |
What was the outcome of reaction 'Gait disturbance'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | Recovered | ReactionOutcome | CC BY | 34204223 | 19,824,593 | 2021-06-17 |
What was the outcome of reaction 'Postural orthostatic tachycardia syndrome'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | Recovered | ReactionOutcome | CC BY | 34204223 | 19,553,314 | 2021-06-17 |
What was the outcome of reaction 'Sleep disorder'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | Recovered | ReactionOutcome | CC BY | 34204223 | 19,824,593 | 2021-06-17 |
What was the outcome of reaction 'Tachycardia'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | Recovered | ReactionOutcome | CC BY | 34204223 | 19,824,593 | 2021-06-17 |
What was the outcome of reaction 'Thinking abnormal'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | Recovered | ReactionOutcome | CC BY | 34204223 | 19,824,593 | 2021-06-17 |
What was the outcome of reaction 'Tremor'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | Recovering | ReactionOutcome | CC BY | 34204223 | 19,824,592 | 2021-06-17 |
What was the outcome of reaction 'Vertigo'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | Recovered | ReactionOutcome | CC BY | 34204223 | 19,824,593 | 2021-06-17 |
What was the outcome of reaction 'Vomiting'? | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and ... | Recovered | ReactionOutcome | CC BY | 34204223 | 19,824,593 | 2021-06-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypotension'. | A Rare Cause of Drug-Induced Pancytopenia: Trimethoprim-Sulfamethoxazole-Induced Pancytopenia.
Pancytopenia is a decrease across cellular hematological lines. Many different etiologies can cause this clinical picture including viral and bacterial infections, chemicals, malignancy, and medications. Particular attention ... | LITHIUM, QUETIAPINE FUMARATE, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY | 34204861 | 19,610,217 | 2021-06-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pancytopenia'. | A Rare Cause of Drug-Induced Pancytopenia: Trimethoprim-Sulfamethoxazole-Induced Pancytopenia.
Pancytopenia is a decrease across cellular hematological lines. Many different etiologies can cause this clinical picture including viral and bacterial infections, chemicals, malignancy, and medications. Particular attention ... | LITHIUM, QUETIAPINE FUMARATE, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY | 34204861 | 19,610,217 | 2021-06-03 |
What was the outcome of reaction 'Hypotension'? | A Rare Cause of Drug-Induced Pancytopenia: Trimethoprim-Sulfamethoxazole-Induced Pancytopenia.
Pancytopenia is a decrease across cellular hematological lines. Many different etiologies can cause this clinical picture including viral and bacterial infections, chemicals, malignancy, and medications. Particular attention ... | Recovering | ReactionOutcome | CC BY | 34204861 | 19,610,217 | 2021-06-03 |
What was the outcome of reaction 'Pancytopenia'? | A Rare Cause of Drug-Induced Pancytopenia: Trimethoprim-Sulfamethoxazole-Induced Pancytopenia.
Pancytopenia is a decrease across cellular hematological lines. Many different etiologies can cause this clinical picture including viral and bacterial infections, chemicals, malignancy, and medications. Particular attention ... | Recovering | ReactionOutcome | CC BY | 34204861 | 19,610,217 | 2021-06-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Pancreatic Injury after COVID-19 Vaccine-A Case Report.
The COVID-19 pandemic has caused more than 3 million deaths worldwide. Recently developed genetically engineered vaccines are the most critical solution for controlling the pandemic. Clinical trials on a large number of participants confirmed their safety and effi... | ACETAMINOPHEN | DrugsGivenReaction | CC BY | 34205898 | 19,586,266 | 2021-06-01 |
What was the administration route of drug 'ACETAMINOPHEN'? | Pancreatic Injury after COVID-19 Vaccine-A Case Report.
The COVID-19 pandemic has caused more than 3 million deaths worldwide. Recently developed genetically engineered vaccines are the most critical solution for controlling the pandemic. Clinical trials on a large number of participants confirmed their safety and effi... | Oral | DrugAdministrationRoute | CC BY | 34205898 | 19,586,266 | 2021-06-01 |
What was the dosage of drug 'ACETAMINOPHEN'? | Pancreatic Injury after COVID-19 Vaccine-A Case Report.
The COVID-19 pandemic has caused more than 3 million deaths worldwide. Recently developed genetically engineered vaccines are the most critical solution for controlling the pandemic. Clinical trials on a large number of participants confirmed their safety and effi... | 2X500 MG | DrugDosageText | CC BY | 34205898 | 19,586,266 | 2021-06-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cutaneous vasculitis'. | Anti-TNF-Related Leukocytoclastic Vasculitis in Ulcerative Colitis: A Case Report.
The development of drugs directed against tumor necrosis factor (TNF)-α has dramatically modified the therapeutic approach to inflammatory bowel diseases: a larger use of such drugs has also led to a major knowledge about their adverse e... | ADALIMUMAB, AZATHIOPRINE, FOLIC ACID, INFLIXIMAB, MESALAMINE | DrugsGivenReaction | CC BY | 34206410 | 19,542,998 | 2021-06-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Anti-TNF-Related Leukocytoclastic Vasculitis in Ulcerative Colitis: A Case Report.
The development of drugs directed against tumor necrosis factor (TNF)-α has dramatically modified the therapeutic approach to inflammatory bowel diseases: a larger use of such drugs has also led to a major knowledge about their adverse e... | ADALIMUMAB, AZATHIOPRINE, FOLIC ACID, INFLIXIMAB, MESALAMINE | DrugsGivenReaction | CC BY | 34206410 | 19,542,998 | 2021-06-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Anti-TNF-Related Leukocytoclastic Vasculitis in Ulcerative Colitis: A Case Report.
The development of drugs directed against tumor necrosis factor (TNF)-α has dramatically modified the therapeutic approach to inflammatory bowel diseases: a larger use of such drugs has also led to a major knowledge about their adverse e... | ADALIMUMAB, AZATHIOPRINE, FOLIC ACID, INFLIXIMAB, MESALAMINE | DrugsGivenReaction | CC BY | 34206410 | 19,542,998 | 2021-06-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use issue'. | Anti-TNF-Related Leukocytoclastic Vasculitis in Ulcerative Colitis: A Case Report.
The development of drugs directed against tumor necrosis factor (TNF)-α has dramatically modified the therapeutic approach to inflammatory bowel diseases: a larger use of such drugs has also led to a major knowledge about their adverse e... | ADALIMUMAB, AZATHIOPRINE, FOLIC ACID, INFLIXIMAB, MESALAMINE | DrugsGivenReaction | CC BY | 34206410 | 19,542,998 | 2021-06-22 |
What was the administration route of drug 'ADALIMUMAB'? | Anti-TNF-Related Leukocytoclastic Vasculitis in Ulcerative Colitis: A Case Report.
The development of drugs directed against tumor necrosis factor (TNF)-α has dramatically modified the therapeutic approach to inflammatory bowel diseases: a larger use of such drugs has also led to a major knowledge about their adverse e... | Subcutaneous | DrugAdministrationRoute | CC BY | 34206410 | 19,542,998 | 2021-06-22 |
What was the administration route of drug 'INFLIXIMAB'? | Anti-TNF-Related Leukocytoclastic Vasculitis in Ulcerative Colitis: A Case Report.
The development of drugs directed against tumor necrosis factor (TNF)-α has dramatically modified the therapeutic approach to inflammatory bowel diseases: a larger use of such drugs has also led to a major knowledge about their adverse e... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34206410 | 19,542,998 | 2021-06-22 |
What was the administration route of drug 'MESALAMINE'? | Anti-TNF-Related Leukocytoclastic Vasculitis in Ulcerative Colitis: A Case Report.
The development of drugs directed against tumor necrosis factor (TNF)-α has dramatically modified the therapeutic approach to inflammatory bowel diseases: a larger use of such drugs has also led to a major knowledge about their adverse e... | Oral | DrugAdministrationRoute | CC BY | 34206410 | 19,542,998 | 2021-06-22 |
What was the dosage of drug 'INFLIXIMAB'? | Anti-TNF-Related Leukocytoclastic Vasculitis in Ulcerative Colitis: A Case Report.
The development of drugs directed against tumor necrosis factor (TNF)-α has dramatically modified the therapeutic approach to inflammatory bowel diseases: a larger use of such drugs has also led to a major knowledge about their adverse e... | IFX EVERY 248 WEEKS AT THE STANDARD DOSE OF 5 MG/KG | DrugDosageText | CC BY | 34206410 | 19,542,998 | 2021-06-22 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.